Last 12 months
Inside the activity.
6 purchase rows · 37 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 21 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 4 | 3 |
| Apr 2026 | 2 | 5 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2022 Filed Jan 21, 2022 16:29 UTC |
Rasmussen RandyChief Financial Officer
|
SaleCommon Stock | 990 | $32.21 | $31,884.34 |
DisclosureSEC source: 0001562180-22-000565 · primarydocument.xml · nonDerivative · entry 1 Rasmussen Randy · CIK 0001860230 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,927 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.75 to $32.72 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 17, 2022 Filed Jan 19, 2022 18:12 UTC |
Davidoff Michael J.See remarks
|
Tax withholdingCommon Stock | 1,231 | $35.55 | $43,762.05 |
DisclosureSEC source: 0001562180-22-000526 · primarydocument.xml · nonDerivative · entry 3 Davidoff Michael J. · CIK 0001777450 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,707 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 17, 2022 Filed Jan 19, 2022 23:06 UTC |
Linetsky DavidSVP, Life Sciences
|
Tax withholdingCommon Stock | 416 | $35.55 | $14,788.80 |
DisclosureSEC source: 0001562180-22-000523 · primarydocument.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,116 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 17, 2022 Filed Jan 19, 2022 23:14 UTC |
VanDuyn Amy BethSVP, Human Resources
|
Tax withholdingCommon Stock | 501 | $35.55 | $17,810.55 |
DisclosureSEC source: 0001562180-22-000527 · primarydocument.xml · nonDerivative · entry 3 VanDuyn Amy Beth · CIK 0001776863 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,509 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 17, 2022 Filed Jan 19, 2022 23:05 UTC |
Roberts EvanChief Operating Officer
|
Tax withholdingCommon Stock | 1,743 | $35.55 | $61,963.65 |
DisclosureSEC source: 0001562180-22-000522 · primarydocument.xml · nonDerivative · entry 3 Roberts Evan · CIK 0001776704 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689,017 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 17, 2022 Filed Jan 19, 2022 23:04 UTC |
Indig ChaimDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 39,206 | $35.55 | $1,393,773.30 |
DisclosureSEC source: 0001562180-22-000521 · primarydocument.xml · nonDerivative · entry 3 Indig Chaim · CIK 0001776732 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,161,581 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 15, 2022 Filed Jan 19, 2022 18:09 UTC |
Rasmussen RandyChief Financial Officer
|
Tax withholdingCommon Stock | 849 | $35.55 | $30,181.95 |
DisclosureSEC source: 0001562180-22-000524 · primarydocument.xml · nonDerivative · entry 2 Rasmussen Randy · CIK 0001860230 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,917 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 15, 2022 Filed Jan 19, 2022 18:12 UTC |
Davidoff Michael J.See remarks
|
Tax withholdingCommon Stock | 4,211 | $35.55 | $149,701.05 |
DisclosureSEC source: 0001562180-22-000526 · primarydocument.xml · nonDerivative · entry 2 Davidoff Michael J. · CIK 0001777450 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,938 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 15, 2022 Filed Jan 19, 2022 23:06 UTC |
Linetsky DavidSVP, Life Sciences
|
Tax withholdingCommon Stock | 4,251 | $35.55 | $151,123.05 |
DisclosureSEC source: 0001562180-22-000523 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,532 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 15, 2022 Filed Jan 19, 2022 23:14 UTC |
VanDuyn Amy BethSVP, Human Resources
|
Tax withholdingCommon Stock | 2,364 | $35.55 | $84,040.20 |
DisclosureSEC source: 0001562180-22-000527 · primarydocument.xml · nonDerivative · entry 2 VanDuyn Amy Beth · CIK 0001776863 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,010 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 15, 2022 Filed Jan 19, 2022 23:10 UTC |
Hoffman Allison CGeneral Counsel & Secretary
|
Tax withholdingCommon Stock | 879 | $35.55 | $31,248.45 |
DisclosureSEC source: 0001562180-22-000525 · primarydocument.xml · nonDerivative · entry 2 Hoffman Allison C · CIK 0001564521 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,227 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 15, 2022 Filed Jan 19, 2022 23:05 UTC |
Roberts EvanChief Operating Officer
|
Tax withholdingCommon Stock | 9,543 | $35.55 | $339,253.65 |
DisclosureSEC source: 0001562180-22-000522 · primarydocument.xml · nonDerivative · entry 2 Roberts Evan · CIK 0001776704 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 690,760 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 15, 2022 Filed Jan 19, 2022 23:04 UTC |
Indig ChaimDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 18,438 | $35.55 | $655,470.90 |
DisclosureSEC source: 0001562180-22-000521 · primarydocument.xml · nonDerivative · entry 2 Indig Chaim · CIK 0001776732 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200,787 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 18:09 UTC |
Rasmussen RandyChief Financial Officer
|
GrantCommon Stock | 53,445 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000524 · primarydocument.xml · nonDerivative · entry 1 Rasmussen Randy · CIK 0001860230 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,766 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Phreesia, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest 6.25% on each quarterly vesting date over four years, beginning on April 14, 2022. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 18:12 UTC |
Davidoff Michael J.See remarks
|
GrantCommon Stock | 35,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000526 · primarydocument.xml · nonDerivative · entry 1 Davidoff Michael J. · CIK 0001777450 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,149 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Phreesia, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest 6.25% on each quarterly vesting date over four years, beginning on April 14, 2022. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:06 UTC |
Linetsky DavidSVP, Life Sciences
|
GrantCommon Stock | 53,445 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000523 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,783 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Phreesia, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest 6.25% on each quarterly vesting date over four years, beginning on April 14, 2022. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:14 UTC |
VanDuyn Amy BethSVP, Human Resources
|
GrantCommon Stock | 22,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000527 · primarydocument.xml · nonDerivative · entry 1 VanDuyn Amy Beth · CIK 0001776863 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,374 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Phreesia, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest 6.25% on each quarterly vesting date over four years, beginning on April 14, 2022. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:10 UTC |
Hoffman Allison CGeneral Counsel & Secretary
|
GrantCommon Stock | 35,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000525 · primarydocument.xml · nonDerivative · entry 1 Hoffman Allison C · CIK 0001564521 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,106 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Phreesia, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest 6.25% on each quarterly vesting date over four years, beginning on April 14, 2022. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:05 UTC |
Roberts EvanChief Operating Officer
|
GrantCommon Stock | 53,445 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000522 · primarydocument.xml · nonDerivative · entry 1 Roberts Evan · CIK 0001776704 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,303 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Phreesia, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest 6.25% on each quarterly vesting date over four years, beginning on April 14, 2022. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 23:04 UTC |
Indig ChaimDirector · Chief Executive Officer
|
GrantCommon Stock | 91,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000521 · primarydocument.xml · nonDerivative · entry 1 Indig Chaim · CIK 0001776732 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,219,225 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the Phreesia, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest 6.25% on each quarterly vesting date over four years, beginning on April 14, 2022. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 23:19 UTC |
Roberts EvanChief Operating Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 43,750 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001562180-22-000434 · primarydocument.xml · derivative · entry 2 Roberts Evan · CIK 0001776704 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,750 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 23:19 UTC |
Roberts EvanChief Operating Officer
|
Exercise / conversionCommon Stock | 43,750 | $0.84 | $36,750.00 |
DisclosureSEC source: 0001562180-22-000434 · primarydocument.xml · nonDerivative · entry 1 Roberts Evan · CIK 0001776704 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:17 UTC |
Indig ChaimDirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 84,270 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001562180-22-000399 · primarydocument.xml · derivative · entry 3 Indig Chaim · CIK 0001776732 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 84,270 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:17 UTC |
Indig ChaimDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 84,270 | $2.03 | $171,068.10 |
DisclosureSEC source: 0001562180-22-000399 · primarydocument.xml · nonDerivative · entry 1 Indig Chaim · CIK 0001776732 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,127,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:16 UTC |
Linetsky DavidSVP, Life Sciences
|
Exercise / conversionStock Options (Right to buy) · Derivative | 5,688 | $0.00 Strike: $8.03 | $0.00 |
DisclosureSEC source: 0001562180-22-000336 · primarydocument.xml · derivative · entry 6 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,689 Underlying: Common Stock · 5,688 shares Expires 2029-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of this option vested and became exercisable on January 17, 2020, with the remainder vesting in three (3) equal annual installments thereafter. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:16 UTC |
Linetsky DavidSVP, Life Sciences
|
Exercise / conversionStock Options (Right to buy) · Derivative | 948 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001562180-22-000336 · primarydocument.xml · derivative · entry 5 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475 Underlying: Common Stock · 948 shares Expires 2028-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option vested and became exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:16 UTC |
Linetsky DavidSVP, Life Sciences
|
Exercise / conversionStock Options (Right to buy) · Derivative | 24,314 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001562180-22-000336 · primarydocument.xml · derivative · entry 4 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,689 Underlying: Common Stock · 24,314 shares Expires 2028-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of this option vested and became exercisable on August 7, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:16 UTC |
Linetsky DavidSVP, Life Sciences
|
Exercise / conversionCommon Stock | 5,688 | $8.03 | $45,674.64 |
DisclosureSEC source: 0001562180-22-000336 · primarydocument.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:16 UTC |
Linetsky DavidSVP, Life Sciences
|
Exercise / conversionCommon Stock | 948 | $4.71 | $4,465.08 |
DisclosureSEC source: 0001562180-22-000336 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:16 UTC |
Linetsky DavidSVP, Life Sciences
|
Exercise / conversionCommon Stock | 24,314 | $4.71 | $114,518.94 |
DisclosureSEC source: 0001562180-22-000336 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 16:46 UTC |
Davidoff Michael J.See remarks
|
Exercise / conversionStock Options (Right to buy) · Derivative | 6,399 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001562180-22-000088 · primarydocument.xml · derivative · entry 2 Davidoff Michael J. · CIK 0001777450 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 712 Underlying: Common Stock · 6,399 shares Expires 2028-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 16:46 UTC |
Davidoff Michael J.See remarks
|
Exercise / conversionCommon Stock | 6,399 | $4.71 | $30,139.29 |
DisclosureSEC source: 0001562180-22-000088 · primarydocument.xml · nonDerivative · entry 1 Davidoff Michael J. · CIK 0001777450 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 18:49 UTC |
Rasmussen RandyChief Financial Officer
|
GrantCommon Stock | 342 | $35.41 | $12,110.22 |
DisclosureSEC source: 0001562180-22-000291 · primarydocument.xml · nonDerivative · entry 1 Rasmussen Randy · CIK 0001860230 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,321 F1 · kind: Shares purchased pursuant to the Phreesia, Inc. 2019 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2021 through December 31, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 31, 2021. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 23:47 UTC |
Hoffman Allison CGeneral Counsel & Secretary
|
GrantCommon Stock | 137 | $35.41 | $4,851.17 |
DisclosureSEC source: 0001562180-22-000290 · primarydocument.xml · nonDerivative · entry 1 Hoffman Allison C · CIK 0001564521 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,945 F1 · kind: Shares purchased pursuant to the Phreesia, Inc. 2019 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2021 through December 31, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 31, 2021. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 31, 2021 Filed Jan 5, 2022 23:46 UTC |
Indig ChaimDirector · Chief Executive Officer
|
GiftCommon Stock | 255,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000289 · primarydocument.xml · nonDerivative · entry 1 Indig Chaim · CIK 0001776732 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043,535 F1 · kind: The shares were transferred in a transaction exempt from Section 16(b) under Rule 16b-5, as a bona fide gift. The Reporting Person is voluntarily reporting this transaction on Form 4 before the applicable Form 5 deadline. F2 · shares: On December 31, 2021, the Reporting Person transferred 255,000 shares of Phreesia, Inc. common stock to a family trust of which the Reporting Person's sister-in-law is the investment advisor and distribution advisor. Members of the Reporting Person's immediate family are the sole beneficiaries of such trust. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 21:08 UTC |
Roberts EvanChief Operating Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 50,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001562180-21-007624 · primarydocument.xml · derivative · entry 2 Roberts Evan · CIK 0001776704 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 Underlying: Common Stock · 50,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 21:08 UTC |
Roberts EvanChief Operating Officer
|
Exercise / conversionCommon Stock | 50,000 | $0.84 | $42,000.00 |
DisclosureSEC source: 0001562180-21-007624 · primarydocument.xml · nonDerivative · entry 1 Roberts Evan · CIK 0001776704 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 603,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 21:08 UTC |
Indig ChaimDirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 50,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001562180-21-007623 · primarydocument.xml · derivative · entry 2 Indig Chaim · CIK 0001776732 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,270 Underlying: Common Stock · 50,000 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 21:08 UTC |
Indig ChaimDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 50,000 | $2.03 | $101,500.00 |
DisclosureSEC source: 0001562180-21-007623 · primarydocument.xml · nonDerivative · entry 1 Indig Chaim · CIK 0001776732 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,298,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 16:12 UTC |
Rasmussen RandyChief Financial Officer
|
SaleCommon Stock | 7,185 | $73.98 | $531,541.27 |
DisclosureSEC source: 0001562180-21-007016 · primarydocument.xml · nonDerivative · entry 1 Rasmussen Randy · CIK 0001860230 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,979 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 21:50 UTC |
Linetsky DavidSVP, Life Sciences
|
Exercise / conversionStock Option · Derivative | 1,499 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001562180-21-006937 · primarydocument.xml · derivative · entry 6 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,423 Underlying: Common Stock · 1,499 shares Expires 2028-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 21:50 UTC |
Linetsky DavidSVP, Life Sciences
|
SaleCommon Stock | 1,499 | $75.12 | $112,606.98 |
DisclosureSEC source: 0001562180-21-006937 · primarydocument.xml · nonDerivative · entry 4 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,388 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.32 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 21:50 UTC |
Linetsky DavidSVP, Life Sciences
|
Exercise / conversionCommon Stock | 1,499 | $4.71 | $7,060.29 |
DisclosureSEC source: 0001562180-21-006937 · primarydocument.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 06, 2021 Filed Nov 9, 2021 16:50 UTC |
Rasmussen RandyChief Financial Officer
|
Tax withholdingCommon Stock | 2,862 | $73.81 | $211,244.22 |
DisclosureSEC source: 0001562180-21-006936 · primarydocument.xml · nonDerivative · entry 1 Rasmussen Randy · CIK 0001860230 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,164 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:50 UTC |
Linetsky DavidSVP, Life Sciences
|
Exercise / conversionStock Option · Derivative | 3,478 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001562180-21-006937 · primarydocument.xml · derivative · entry 5 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,922 Underlying: Common Stock · 3,478 shares Expires 2028-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:50 UTC |
Linetsky DavidSVP, Life Sciences
|
SaleCommon Stock | 3,478 | $75.15 | $261,382.48 |
DisclosureSEC source: 0001562180-21-006937 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,388 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:50 UTC |
Linetsky DavidSVP, Life Sciences
|
Exercise / conversionCommon Stock | 3,478 | $4.71 | $16,381.38 |
DisclosureSEC source: 0001562180-21-006937 · primarydocument.xml · nonDerivative · entry 1 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:37 UTC |
Linetsky DavidSVP, Life Sciences
|
Exercise / conversionStock Option · Derivative | 5,451 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001562180-21-006772 · primarydocument.xml · derivative · entry 4 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,400 Underlying: Common Stock · 5,451 shares Expires 2028-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 31, 2019, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:37 UTC |
Linetsky DavidSVP, Life Sciences
|
SaleCommon Stock | 3,077 | $71.23 | $219,187.02 |
DisclosureSEC source: 0001562180-21-006772 · primarydocument.xml · nonDerivative · entry 3 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,388 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.85 to $71.50 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:37 UTC |
Linetsky DavidSVP, Life Sciences
|
SaleCommon Stock | 2,374 | $70.42 | $167,174.71 |
DisclosureSEC source: 0001562180-21-006772 · primarydocument.xml · nonDerivative · entry 2 Linetsky David · CIK 0001776729 · SVP, Life Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,465 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.85 to $70.79 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.